Our NYC team will be attending the Metropolitan Hospital Center’s Rare Disease Day event. Learn more and register for an exciting afternoon with physicians, patients, and caregivers dedicated to rare disease awareness. http://bit.ly/2l2B4K3
Ahead of Rare Disease Day next Tuesday, we’ll be raising awareness for the day and the community across all of our social channels this week. Check back in to learn more about this unique community!
What qualifies as a rare disease? Any disease, disorder, illness or condition affecting fewer than 200,000 people in the US is considered rare. 7,000 rare diseases exist and only 5% have FDA-approved treatments. Learn more: http://bit.ly/RDDFacts
Principal Jillian Godfrey Scaife recently spoke with Specialty Pharmacy Times about the impact that the FDA’s recent biosimilar interchangeability draft guidance will have on specialty pharmacy. Read the Q&A here: http://bit.ly/2jZdudr
Members of the Trinity team recently researched adherence to clinic recommendations among patients with phenylketonuria. Review their findings on Molecular Genetics and Metabolism: http://bit.ly/2kAM9lE
Taking place January 9-13, one of our partners, Herman Sanchez, is at the industry event, which brings together thousands of investors and executives from around the world to see companies present their latest innovations, hoping to find their next partner or investor.
Trinity Partners today, in concert with the 35th Annual JP Morgan Healthcare Conference, has announced the findings of a white paper exploring the strategic decisions that successfully position a company for a maximized M&A exit. By examining the past ten years of biopharma M&A activity, Trinity has developed a framework that summaries the optimal path for private companies, taking into consideration major factors that inform valuations including financials, R&D portfolio, licensing opportunities, partnerships and more.
Download the whitepaper HERE
In a Q&A with Contract Pharma Editor Kristin Brooks, Trinity Founder and President John Corcoran discusses advances in science and technology, changing global healthcare markets and patient needs, along with the pharma and biopharmaceutical industry’s R&D efforts and evolving business models. Read the Q&A here: http://bit.ly/2iFDnzW
In the December issue of PM360, Partner Stephen Fleming discussed the life science industry’s biggest lessons learned in 2016, as well as potential challenges ahead in 2017. Stephen remarked on the importance of providing early-stage pharmaceutical/biotech companies with commercial support so they can independently develop and launch their drugs. He also discussed the importance of leveraging not only the commercial side, but also payer/access and patient perspectives throughout pre-launch work. In addition, Stephen highlighted challenges in value communication as an area of focus for the year ahead. Read Stephen’s complete commentary: http://bit.ly/2iERrw8
Trinity Partners President John Corcoran Discusses The Future of Drug Launches
John Corcoran, President of Trinity Partners, shared his expertise on the future of drug launches with FiercePharma. See the full article here: http://bit.ly/2h3DR1J